NFE2L2 and breast cancer: According to a recent report, long-term treatment with hypoglycemic drugs such as dipeptidyl peptidase-4 inhibitors in an animal model of breast cancer triggered ROS overproduction and activated the ROS-dependent Nrf2 and HO-1 genes.